BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Be at the forefront of the Bispecific space as it goes head to
  head with cell therapy to transform oncology. Among numerous innovations
  in cancer immunotherapy\, Bispecific antibody treatments have never been
  more promising with continuous clinical updates and approvals over the l
 ast year\, including the huge waves seen in multiple myeloma and lymphoma
  treatment.\n\nThe World Bispecific Summit returns for its 14th year with
  an enriched program boasting comprehensive coverage of all the key disco
 very\, pre-clinical and clinical challenges including design\, clinical\,
  regulatory and combination strategies. Led by the industry's brightest m
 inds from the likes of Sanofi\, Regeneron\, the FDA\, Alligator Bioscienc
 es and Amgen\, it's the perfect platform to celebrate wins\, work through
  challenges and establish connections with the leading pharma\, biotech a
 nd academic KOLs.\n\nDeep dive into novel target selection\, immune cell 
 modulators\, target selection and pre-clinical/clinical readouts and gain
  holistic insight on the current state-of-play in the bispecific landscap
 e to supercharge your own pipeline from discovery through to IND approval
 .\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1780206-2?pid=185Brochure:&
 nbsp\;https://go.evvnt.com/1780206-3?pid=185Twitter:&nbsp\;https://go.evv
 nt.com/1780206-4?pid=185LinkedIn:&nbsp\;https://go.evvnt.com/1780206-5?pi
 d=185\n\nPrices:Conference Only - Service Provider: USD 3599.00\,Conferen
 ce + Seminar Day - Service Provider: USD 5696.00\,Conference Day Only - A
 cademic Pricing: USD 2499.00\,Conference + Seminar Day - Academic Pricing
 : USD 3996.00\,Conference Only &nbsp\;- Drug Developer: USD 2899.00\,Conf
 erence + Seminar Day - Drug Developer: USD 4696.00\n\nSpeakers:&nbsp\;Ale
 xander Schinagl\, Chief Technology Officer\, OncoOne\, Anish Suri\, Presi
 dent and Chief Scientific Officer\, Cue Biopharma\, Arne Scheu\, Co-Found
 er and Chief Executive Officer\, LiliumX\, Christoph Rader\, Chief Techno
 logy Officer\, Aethon Therapeutics\, Christopher Mehlin\, Co-Founder and 
 Chief Scientific Officer\, Link Immunotherapeutics Inc.\, Colette Johnsto
 n\, Vice President\, Discovery\, Crescendo Biologics\, Daniel Bedinger\, 
 Application Science Manager\, Carterra\, Ercole Rao Group Leader - Biolog
 ics Research and Engineered Protein Therapeutics\, Sanofi\, Giorgio SALCI
 ARINI\, Marketing and Business Development Manager\, BSP Pharmaceuticals\
 , Hayretin Yumerefendi\, Associate Director\, Novartis\, Johannes Nelke\,
  Senior Scientist Bispecific Antibodies\, &nbsp\;BioNTech SE\, John Burke
  President\, Chief Executive Officer and Co-Founder Applied BioMath\, Juh
 a Punnonen\, Chief Development Officer\, Hinge Bio\, Inc.\, Kara Olson\, 
 Fellow Scientist\, Regeneron Pharmaceuticals Inc\, Kartik Krishnan\, Chie
 f Medical Officer\, OncoNano Medicine Inc.\, Ken Howard\, Associate Profe
 ssor and Group Leader - Interdisciplinary Nanoscience Centre (iNANO)\, Aa
 rhus University\, Kerry Casey\, Associate Director - Precision Medicine\,
  Regeneron Pharmaceuticals Inc\, Marjorie Shapiro\, Chief of Laboratory o
 f Molecular and Developmental Immunology\, US Food and Drug Administratio
 n (FDA)\, Mattias Levin Director - Antibody Technology Innovation\, &nbsp
 \;Alligator Bioscience AB\, Michael Groaning\, Global Medical Affairs Pro
 state Cancer and Early Solid Tumor Pipeline Assets Lead\, Amgen Inc.\, Mi
 ngjiu Chen\, Chief Executive Officer\, Biosion\, Mohamed-Reda Benmebarek\
 , Postdoctoral Fellow\, National Cancer Institute\, Nimish Gera\, Vice Pr
 esident - Biologics Mythic Therapeutics\, Nina Weisser Director - Multisp
 ecific Antibody Therapeutics\, Zymeworks\, Qingcong Lin\, Chief Executive
  Officer\, Biocytogen Boston Corp\, Raffi Tonikian\, Director – Translati
 onal Biomarkers\, Abcellera\, Rakesh Dixit President\, Chief Scientific O
 fficer\, &nbsp\;Regio Biosciences\, Shailee Patel\, Research Analyst\, Be
 acon Intelligence\, Shu-Min Liu President and Chief Executive Officer\, S
 henzhen Enduring Biotech\, Ltd.\, Takamitsu Hattori\, Research Professor\
 , &nbsp\;NYU Grossman School of Medicine\, Thomas Nittoli\, Senior Direct
 or - ADCs\, Regeneron Pharmaceuticals Inc\, Tilman Schlothauer\, Senior P
 rincipal Scientist\, Roche\, Upendra Katneni\, Staff Fellow\, US Food and
  Drug Administration (FDA)\n\nTime:&nbsp\;9:00 am to 4:00 pm\n
DTEND:20231004T160000
DTSTAMP:20260512T223120Z
DTSTART:20231002T090000
LOCATION:Boston Park Plaza\, 50\, Park Plaza\, Boston\, Massachusetts\, 02
 116\,
SEQUENCE:0
SUMMARY:Be at the forefront of the Bispecific space as it goes head to hea
 d with cell therapy to transform oncology. Among numerous innovations in 
 cancer i...
UID:5076c8bd-dd64-43f1-b394-5b950a2e32b7
END:VEVENT
END:VCALENDAR